<DOC>
	<DOCNO>NCT02005536</DOCNO>
	<brief_summary>The aim study assess immunogenicity SP059 ( IMOVAX POLIO® : Inactive Poliovirus Vaccine ) vaccine poliovirus safety fifth dose . Primary Objective : - To investigate booster vaccine response rate poliovirus type 1 , 2 3 one month follow vaccination dose SP059 2nd booster Secondary Objectives : - To investigate seroprotection rate ( percentage subject present poliovirus neutralize antibody titer 1:8 ( 1/dil . ) pre- post-booster time point , Geometric mean titer ( GMT ) pre- post-booster time point geometric mean individual titer ratio ( GMTR ) . - To investigate safety dose SP059 2nd booster .</brief_summary>
	<brief_title>Study IMOVAX POLIO® Subcutaneous Booster Vaccine Pre-school Age Children Japan</brief_title>
	<detailed_description>Participants receive one dose SP059 ( Visit 1 ) booster vaccination age 4 6 year . They assess immunogenicity baseline ( pre-vaccination ) 4-6 week post- vaccination . Safety data include serious adverse event ( SAEs ) vaccination collect study period .</detailed_description>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 4 6 year inclusive day inclusion Subjects receive 4 time IPVcontaining vaccine ( DTaPIPV IPV ) first ( 3 dos ) second year life ( one dose ) Informed consent form sign parent ( ) legal representative Able attend schedule visit comply trial procedure . Fever ≥ 37.5°C ( axillary temperature ) day inclusion Any serious disease whether acute chronic Past current medical history GuillainBarre syndrome , acute thrombocytopenic purpura encephalopathy History poliomyelitis infection History life threaten reaction vaccine contain substance study vaccine History anaphylaxis allergy study vaccine component Congenital current/previous acquire immunodeficiency , immunosuppressive therapy longterm systemic corticosteroid therapy Participation another clinical trial within 6 month trial inclusion Planned participation another clinical trial present trial period Received oral inject antibiotic therapy within 72 hour prior blood draw Received antipyretics/analgesics/Nonsteroidal antiinflammatory drug ( consider single category ) within 4 hour prior vaccination Blood bloodderived product receive past current plan administration trial ( include immunoglobulin ) Any vaccination live vaccine within past 27 day precede trial vaccination Any vaccination inactivate vaccine within past 6 day precede trial vaccination Clinical known serological evidence systemic illness include Hepatitis B , Hepatitis C and/or HIV infection Subject ineligible accord Investigator 's clinical judgment .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Poliomyelitis</keyword>
	<keyword>Poliovirus</keyword>
	<keyword>Polio</keyword>
	<keyword>IMOVAX POLIO®</keyword>
	<keyword>Inactivated polio vaccine</keyword>
</DOC>